All Stories

  1. In silico Optimization of Dihydroorotate dehydrogenase Inhibitors for Malaria viaDocking, Molecular Dynamics, and ADMET Evaluation
  2. Study of Class I HDAC-1, -2, and -3 Inhibitors Designed by Bioisosteric Replacement of Zinc Binding Groups and Caps of Traditional Pan Inhibitors: An In Silico Approach
  3. Covalent Inhibitors - An Overview of Design Process, Challenges and Future Directions
  4. Metronidazole—An Old Drug for Structure Optimization and Repurposing
  5. Diaryl Diimidazopyrimidine Derivatives as Potent Inhibitors of Influenza A Virus: Synthesis, Evaluation and Docking Studies
  6. Virtual screening and molecular fingerprinting for in silico designing of potential CCR5 inhibitors targeting HIV therapy
  7. Biosimilar in Cervical Cancer
  8. LAG-3 Inhibitors for the Treatment of Lung Cancer
  9. Structure-based virtual screening of natural compounds against wild and mutant (R1155K, A1156T and D1168A) NS3-4A protease of Hepatitis C virus
  10. Virtual Screening of a Marine Natural Product Database for In Silico Identification of a Potential Acetylcholinesterase Inhibitor
  11. Vanillin based crosslinked films of CMCh-PVA for wound healing application
  12. Ligand-based pharmacophore modeling and QSAR approach to identify potential dengue protease inhibitors
  13. miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
  14. Pharmacoinformatics based screening of combined synthetic and natural compounds to identify novel and in silico potential Bcl-2 inhibitors
  15. A comprehensive review on acridone based derivatives as future anti-cancer agents and their structure activity relationships
  16. Synthesis and Pharmacological Evaluation of Hexafluoro Functionalized Quinolone Derivatives as Potential Chemotherapeutic Agents
  17. Studies on ligand-based pharmacophore modeling approach in identifying potent future EGFR inhibitors
  18. Computational design of MmpL3 inhibitors for tuberculosis therapy
  19. Development and Characterization of Copper Cross-Linked Freeze-Dried Bioscaffolds for Potential Wound Healing Activity
  20. Supramolecular ternary inclusion complexes of Irbesartan with hydroxypropyl-beta-cyclodextrin
  21. Some metal chelates with Schiff base ligand: synthesis, structure elucidation, thermal behavior, XRD evaluation, antioxidant activity, enzyme inhibition, and molecular docking studies
  22. Enzyme inhibitory function and phytochemical profile of Inula discoidea using in vitro and in silico methods
  23. Ligand-based design approach of potential Bcl-2 inhibitors for cancer chemotherapy
  24. Computational study for identifying promising therapeutic agents of hydroxychloroquine analogues against SARS‐CoV‐2
  25. Screening of natural compounds from Cyperus rotundus Linn against SARS-CoV-2 main protease (Mpro): An integrated computational approach
  26. Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy
  27. Experimental and computational insight of the supramolecular complexes of Irbesartan with β-cyclodextrin based nanosponges
  28. Synthesis, Characterization, Enzyme Inhibitory Activity, and Molecular Docking Analysis of a New Series of Thiophene-Based Heterocyclic Compounds
  29. In silico screening of therapeutic potentials from Strychnos nux-vomica against the dimeric main protease (Mpro) structure of SARS-CoV-2
  30. Study of Combinatorial Drug Synergy of Novel Acridone Derivatives With Temozolomide Using in-silico and in-vitro Methods in the Treatment of Drug-Resistant Glioma
  31. In-silico strategies of some selected phytoconstituents from Melissa officinalis as SARS CoV-2 main protease and spike protein (COVID-19) inhibitors
  32. Transition metal complexes of a multidentate Schiff base ligand containing pyridine: synthesis, characterization, enzyme inhibitions, antioxidant properties, and molecular docking studies
  33. Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis
  34. Potential of Probiotics in the Management of Lung Cancer
  35. In silicoidentification of potential inhibitors fromCinnamonagainst main protease and spike glycoprotein of SARS CoV-2
  36. A Critical Review on Anticancer Mechanisms of Natural Flavonoid Puerarin
  37. In silico approach towards the identification of potential inhibitors from Curcuma amada Roxb against H. pylori: ADMET screening and molecular docking studies
  38. Synthesis of 3, 4-dihydropyrimidin-2(1H)-one derivatives and evaluation of their antibacterial activity
  39. Design Potent Telomerase Inhibitors Using Structure Based Approaches
  40. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy
  41. Reappraisal of FDA approved drugs against Alzheimer’s disease based on differential gene expression and protein interaction network analysis: an in silico approach
  42. Hit identification and drug repositioning of potential non-nucleoside reverse transcriptase inhibitors by structure-based approach using computational tools (part II)
  43. Improved treatment efficacy of risedronate functionalized chitosan nanoparticles in osteoporosis: formulation development, in vivo, and molecular modelling studies
  44. Design of metronidazole derivatives and flavonoids as potential non-nucleoside reverse transcriptase inhibitors using combined ligand- and structure-based approaches
  45. Ligand based design and synthesis of pyrazole based derivatives as selective COX-2 inhibitors
  46. Synthesis of novel gefitinib‐based derivatives and their anticancer activity
  47. An update on Drug Repurposing: Re-written saga of the drug’s fate
  48. Role of Natural Products in Glaucoma Management
  49. Host-guest interaction study of Efavirenz with hydroxypropyl‑β‑cyclodextrin and l‑arginine by computational simulation studies: Preparation and characterization of supramolecular complexes
  50. Study on effect of L-arginine on solubility and dissolution of Zaltoprofen: Preparation and characterization of binary and ternary cyclodextrin inclusion complexes
  51. Phytochemicals and PI3K Inhibitors in Cancer—An Insight
  52. Acridone-pyrimidine hybrids- design, synthesis, cytotoxicity studies in resistant and sensitive cancer cells and molecular docking studies
  53. Complexation of phytochemicals with cyclodextrin derivatives – An insight
  54. Design, synthesis, biological evaluation, molecular docking and QSAR studies of 2,4-dimethylacridones as anticancer agents
  55. Inclusion Complexes of Nateglinide with HP–β–CD and L-Arginine for Solubility and Dissolution Enhancement: Preparation, Characterization, and Molecular Docking Study
  56. Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies
  57. Current Overview on the Usage of Poly(ADP-ribose)polymerase (PARP) Inhibitors in Treating Cancer
  58. Identification and Usage of Fluorescent Probes as Nanoparticle Contrast Agents in Detecting Cancer